Last reviewed · How we verify
NCT05656963
The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
trial testing Grouping based on previous laboratory results, no intervention. in Glomerulonephritis, Membranous in 741 participants. Status unknown.
30 October 2023
Quick facts
| Lead sponsor | Yipeng Liu |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 741 |
| Start date | 1 September 2021 |
| Primary completion | 30 October 2023 |
| Estimated completion | 31 January 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Grouping based on previous laboratory results, no intervention.
Conditions studied
- Glomerulonephritis, Membranous — all drugs for Glomerulonephritis, Membranous →
- Diabetic Nephropathies — all drugs for Diabetic Nephropathies →
- Thrombelastography — all drugs for Thrombelastography →
- Thromboembolism — all drugs for Thromboembolism →
Sponsor
Yipeng Liu
Who can join
Adults 18 to 70, any sex, with Glomerulonephritis, Membranous or Diabetic Nephropathies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Influence factors and preliminary mechanism of high incidence of thrombotic events in patients with idiopathic membranous nephropathy and diabetes kidney disease
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05656963
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Grouping based on previous laboratory results, no intervention.
Trials testing the same drug.
- NCT06123871 — Expression Analysis of Urinary Exosome in Type 2 Diabetic Kidney Disease and Evaluation of Its Clinical Diagnostic Value · unknown
- NCT06097351 — Expression Analysis of Urinary Exosome in Type 2 Diabetic Nephropathy and Evaluation of Its Clinical Diagnostic Value · unknown
Other recruiting trials for Glomerulonephritis, Membranous
Currently open trials in the same condition.
- NCT05914155 — Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome · Phase 3 · recruiting
Other Yipeng Liu trials
Trials by the same sponsor.
- NCT07069972 — A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimum · not yet recruiting
- NCT07053137 — A Comparative Study of the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythema · active not recruiting
- NCT07031674 — Comparing Efficacy and Safety of Telitacicept and Belimumab in Lupus Nephritis: A Retrospective Multicenter Cohort Study · completed
- NCT06123871 — Expression Analysis of Urinary Exosome in Type 2 Diabetic Kidney Disease and Evaluation of Its Clinical Diagnostic Value · unknown
- NCT06097351 — Expression Analysis of Urinary Exosome in Type 2 Diabetic Nephropathy and Evaluation of Its Clinical Diagnostic Value · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05656963 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yipeng Liu
- Last refreshed: 18 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05656963.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing